Replies to post #189782 on Biotech Values

[GrthzGd]

Anything of note relative to NASH?

[DewDiligence]

The abstract on fluctuating baseline levels of HCV is potentially a market-moving finding if it turns out that the criteria for shortening Harvoni treatment to 8 weeks in the FDA label can’t be reliably applied in practice.

[jq1234]

SOF/GS-5816 plus GS-9857 FDC in 4/6 weeks regimen:

Presented as a late-breaker ePoster (ePoster #LP03), a Phase 2 study of triple-combination therapy with a fixed-dose combination of SOF/GS-5816 plus GS-9857 among genotype 1 patients demonstrated sustained virologic response (SVR12) rates following six weeks of treatment of 93 percent (n=14/15) among treatment-naïve, non-cirrhotic patients, 87 percent (n=13/15) among treatment-naïve, cirrhotic patients, and 67 percent (n=20/30) among those who had failed therapy with two or more direct-acting antiviral agents (DAAs). The four-week regimen resulted in a sub-optimal SVR12 rate of 27 percent (n=4/15).

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2039076